In this regard, development of a pharmacological inhibition therapy targeting SphK1 is a useful therapeutic strategy for both early and late stages of cancer, although no specific inhibitors targeting SphK1 have been developed as yet57. The gene discussed is SPHK1; the disease is cancer.